<!DOCTYPE html>
<html class="no-js">
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <title>ONCOGERIATRIA</title>
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta name="description" content="oncogeriatria" />
    <meta name="keywords" content="oncologia, oncogeriatria, medicina" />
    <meta name="author" content="e-oncologia" />

    <link rel="shortcut icon" type="image/png" href="images/logo.png" />

    <link
      href="https://fonts.googleapis.com/css?family=Roboto:400,300,600,400italic,700"
      rel="stylesheet"
      type="text/css"
    />
    <link
      href="https://fonts.googleapis.com/css?family=Montserrat:400,700"
      rel="stylesheet"
      type="text/css"
    />

    <link rel="stylesheet" href="css/animate.css" />
    <link rel="stylesheet" href="css/icomoon.css" />
    <link rel="stylesheet" href="css/bootstrap.css" />
    <link rel="stylesheet" href="css/owl.carousel.min.css" />
    <link rel="stylesheet" href="css/owl.theme.default.min.css" />
    <link rel="stylesheet" href="css/style.css" />
    <script src="js/modernizr-2.6.2.min.js"></script>
  </head>

  <body>
    <div id="ico-page">
      <a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>
      <aside
        id="ico-aside"
        role="complementary"
        class="border js-fullheight"
        style="background-image: url(images/BGoscuro.jpg);"
      >
        <p><br /></p>
        <h2 id="ico-logo">
          <a href="index.html"><img src="images/logo.png" height="80"/></a>
        </h2>
        <nav id="ico-main-menu" role="navigation">
          <ul>
            <li>
              <a href="m1A.html"
                ><span class="bgdestacado1">MÓDULO 1</span><br />VALORACIÓN DEL
                ANCIANO CON CÁNCER</a
              >
            </li>
            <ol>
              <li><a href="m1A.html">Introducción</a></li>
              <li><a href="m1B.html">Envejecimiento poblacional</a></li>
              <li><a href="m1C.html">Evaluación del anciano</a></li>
              <li><a href="m1D.html">Valoración geriátrica integral</a></li>
              <li><a href="m1E.html">Herramientas de cribado</a></li>
              <li><a href="m1F.html">Toma de decisiones</a></li>
              <li><a href="m1G.html">Organización de la atención</a></li>
              <li><a href="m1H.html">Resumen</a></li>
              <li>
                <a href="m1I.html"
                  ><span class="bgdestacado2">Bibliografía</span></a
                >
              </li>
            </ol>
            <br />
            <li>
              <a href="m2A.html"
                ><span class="bgdestacado1">MÓDULO 2</span><br />QUIMIOTERAPIA Y
                NUEVOS TRATAMIENTOS</a
              >
            </li>
            <ol>
              <li><a href="m2A.html">Eficacia de la quimioterapia</a></li>
              <li><a href="m2B.html">Terapias dirigidas</a></li>
              <li><a href="m2C.html">Inmunoterapia</a></li>
              <li>
                <a href="m2D.html">Toxicidad en tto. antineoplasico</a>
              </li>
              <li>
                <a href="m2E.html"
                  ><span class="bgdestacado2">Bibliografía</span></a
                >
              </li>
            </ol>
          </ul>
        </nav>
      </aside>
      <div id="ico-main">
        <div class="ico-cabecera">
          <div class="ico-narrow-content animate-box">
            <h4 class="text-center">
              Quimioterapia y nuevos tratamientos en oncogeriatría. Eficacia,
              toxicidad y manejo
            </h4>
            <img
              src="images/ICONOabuelito2.png"
              alt=""
              class="img-responsive centrada"
            />
          </div>
        </div>

        <div class="ico-narrow-content">
          <div class="row animate-box" data-animate-effect="fadeInLeft">
            <div class="col-md-12">
              <h3>Bibliografía</h3>

              <p>
                Alexandre J, Gross-Goupil M, Falissard B, et al. Evaluation of
                the nutritional and inflammatory status in cancer patients for
                the risk assessment of severe haematological toxicity following
                chemotherapy. Ann Oncol. 2003;14(1):36-41.
              </p>
              <p>
                Aparicio T, Bouche O, Francois E, et al. PRODIGE 20: bevacizumab
                + chemotherapy (BEV-CT) versus chemotherapy alone in elderly
                patients with untreated metastatic colorectal cancer- a
                randomized phase II trial. J Clin Oncol. 2015;33(Suppl).
              </p>
              <p>
                Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as
                independent prognostic factors in the treatment of non-small
                cell lung cancer: a review of National Cancer Institute of
                Canada Clinical Trials Group trials. J Clin Oncol.
                2008;26(1):54-9.
              </p>
              <p>
                Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as
                independent prognostic factors in the treatment of non
                small-cell lung cancer: a review of National Cancer Institute of
                Canada Clinical Trials Group trials. J Clin Oncol. 2008;26:54-9.
              </p>
              <p>
                Asimakopoulou N, Souglakos J, Kentepozidis N, et al. Efficaccy
                of panitumumab in older patients with metastatic colorectal
                cancer: a retrospective analysis using the database of the
                Hellenic Oncology Research Group (HORG). J Geriatr Oncol
                2019;10:143-48.
              </p>
              <p>
                Bastiaannet E, Battisti N, Loh KP, et al. Immunotherapy and
                targeted therapies in older patients with advanced melanoma;
                Young International Society of Geriatric Oncology review
                paper.J. Geriatr Oncol 2019;10(3):389-97.
              </p>
              <p>
                Battaglin F, Schirripa M, Buggin F, et al. The PANDA study: a
                randomized phase II study of first-line FOLFOX plus panitumumab
                versus 5FU plus panitumumab in RAS and BRAF wild-type elderly
                metastatic colorectal cancer patients. BMC Cancer 2018;18:98.
              </p>
              <p>
                Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of
                platinum-based chemotherapy in patients older and younger than
                70 years: an analysis of Southwest Oncology Group Trials 9308
                and 9509. J Thorac Oncol. 2011;6:115-20.
              </p>
              <p>
                Beinse G, Emile G, Cessot A, et al. A real-life experience of
                bevacizumab in elderly women iwith advanced ovarian carcinoma.
                Int J Gynecol Cancer. 2016;26(7):1196-200.
              </p>
              <p>
                Begg CB, Carbone PP. Clinical trials and drug toxicity in the
                elderly. The experience of the Eastern Cooperative Oncology
                Group. Cancer. 1983;52:1986-92.
              </p>
              <p>
                Brain E, Caillet P, de Glas N, et al. HER2-targeted treatment
                for older patients with breast cancer: An expert position paper
                from the International Society of Geriatric Oncology. J Geriatr
                Oncol. 2019 Jun 21. pii: S1879-4068(18)30479-X. doi:
                10.1016/j.jgo.2019.06.004. [Epub ahead of print].
              </p>
              <p>
                Brollo J, Curigliano G, Disalvatore D, et al. Adjuvant
                trastuzumab in elderly with HER-2 positive breast cancer: A
                systematic review of randomized controlled trials. Cancer Treat
                Rev. 2013;39(1):44-50.
              </p>
              <p>
                Chen H, Cantor A, Meyer J, et al. Can older cancer patients
                tolerate chemotherapy? A prospective pilot study. Cancer.
                2003;97(4):1107-14.
              </p>
              <p>
                Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic
                breast cancer in the elderly. The Piedmont Oncology Association
                experience. JAMA. 1992;268(1):57-62.
              </p>
              <p>
                Creditor MC. Hazards of hospitalization of the elderly. Ann
                Intern Med. 1993;118:219-23.
              </p>
              <p>
                Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus
                capecitabine versus capecitabine alone in elderly patients with
                previously untreated metastatic colorectal cancer (AVEX): an
                open-label, randomised phase 3 trial. Lancet Oncol.
                2013;14(11):1077-85.
              </p>
              <p>
                Cowey CL, Liu FX, Bloack-Shinn J, et al. Pembrolizumab
                utilization and outcomes for advanced melanoma in US community
                oncology practices. J Immunother. 2018;41:86-95.
              </p>
              <p>
                Cruz-Jentoft AJ, Bahat G, Bauer J, et al; Writing Group for the
                European Working Group on Sarcopenia in Older People 2
                (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia:
                revised European consensus on definition and diagnosis. Age
                Ageing. 2019;48:16-31.
              </p>
              <p>
                Daly LE, Power DG, O’Reilly A, et al. The impact of body
                composition parameters on ipilimumab toxicity and survival in
                patients with metastatic melanoma. Br J Cancer. 2017;116:310-17.
              </p>
              <p>
                Daste A, Chakiba C, Domblides C, et al. Targeted therapy and
                elderly people: a review. Eur J Cancer. 2016;69:199-215.
              </p>
              <p>
                Daste A, Domblides Ch, Gross-goupil M, et al. Immune checkpoint
                inhibitors and elderly people: a review. European J Cancer
                2017;82:155-66.
              </p>
              <p>
                Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for
                multidimensional health problems warranting a geriatric
                assessment in older cancer patients: an update on SIOG
                recommendations. Ann Oncol. 2015;26(2):288-300.
              </p>
              <p>
                Elias R, Karantanos T, Sira E, et al. Immunotherapy comes of
                age: immune aging and checkpoint inhibitors. J Geriatr Oncol.
                2017;8:229-35.
              </p>
              <p>
                Elias R, Giobbie-Hurder A, McCleary NJ, et al. Efficacy of PD-1
                and PD-L1 inhibitors in older adults: a meta-analysis. J
                Immunother Cancer. 2018;6:26.
              </p>
              <p>
                Elias R, Odejide O. Immunotherapy in older adults: A checkpoint
                to palliation?. Am Soc Clin Oncol Educ Book. 2019;39:e110-e120.
              </p>
              <p>
                Esther J, Hale P, Wahn AW, Agarwal N, et al. Treatment decisions
                for metastatic clerar cell rnal cell carcinoma in older
                patients: the role of TKIs and immune checkpoints inhibitors.
                Drugs Aging 2019;36:395-401.
              </p>
              <p>
                Extermann M, Boler I, Reich RR, et al. Predicting the risk of
                chemotherapy toxicity in older patients: the Chemotherapy Risk
                Assessment Scale for High-Age Patients (CRASH) score. Cancer.
                2012;118:3377-86.
              </p>
              <p>
                Feliu J, Heredia-Soto V, Gironés R, et al. Can we avoid the
                toxicity of chemotherapy in elderly cancer patients?. Crit Rev
                Oncol Hematol. 2018;131:16-23.
              </p>
              <p>
                Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group.
                Regorafenib monotherapy for previously treated metastatic
                colorectal cancer (CORRECT): an international, multicentre,
                randomised, placebo-controlled, phase 3 trial. Lancet.
                2013;381(9863):303-12.
              </p>
              <p>
                Glück S, von Minckwitz G, Untch M. Aromatase inhibitors in the
                treatment of elderly women with metastatic breast cancer.
                Breast. 2013;22(2):142-49.
              </p>
              <p>
                Gomes F, Tay R, Chiramel J, et al. The role of targeted agents
                and immunotherapy in older patients with non-small cell lung
                cancer. Drugs Aging 2018;35:819-34.
              </p>
              <p>
                Gouverneur A, Coutureau J, Jové J, et al. Patterns of use,
                safety, and effectiveness of targeted therapies in first-line
                treatment of metastatic colorectal cancer according to age: the
                STROMBOLI cohort study. Clin Colorectal Cancer
                2018;18(1):e150-62.
              </p>
              <p>
                Hale P, Hahn AW, Rathi N, et al. Treatment of metastatic renal
                cell carcinoma in older patients: A network meta-analysis. J
                Geriatr Oncol 2019;149-54.
              </p>
              <p>
                Haller DG, O’Connell MJ, Cartwright TH, et al. Impact of age and
                medical comorbidity on adjuvant treatment outcomes for stage III
                colon cancer: a pooled analysis of individual patient data from
                four randomized, controlled trials. Ann Oncol. 2015;26:715-24.
              </p>
              <p>
                Havel JJ, CHowell D, Chan TA. The evolving landscape of
                biomarkers for checkpoint inhibitor immunotherapy. Nat Rev
                Cancer. 2019;19:133-50.
              </p>
              <p>
                Hurria A, Gupta S, Zauderer M, et al. Developing a
                cancer-specific geriatric assessment: a feasibility study.
                Cancer. 2005;104(9):1998-2005.
              </p>
              <p>
                Helissey C, Vicier C, Champiat S. The development of
                inmunotherapy in olders adults: New treatments, news
                toxicities?. J. Geriatric Oncol. 2016;5:325-33.
              </p>
              <p>
                Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy
                toxicity in older adults withcancer: a prospective multicenter
                study. J Clin Oncol. 2011;29:3457-65.
              </p>
              <p>
                Hurria A, Dale W, Mooney M, et al. Designing therapeutic
                clinical trials for older and frail adults with cancer: U13
                conference recommendations. J Clin Oncol. 2014;32(24):2587-94.
              </p>
              <p>
                Ito S, Ito H, Sato N, et al. Clinical factors associated with
                the therapeutic outcome of chemotherapy in very elderly cancer
                patients. Int J Clin Oncol. 2019;24(5):596-601.
              </p>
              <p>
                Jolivet J, Cowan KH, Curt GA, et al. The pharmacology and
                clinical use of methotrexate. N Engl J Med. 1983;309:1094-104.
              </p>
              <p>
                Kasherman L, Siu DHW, Lee KWC, et al. Efficacy of immune
                checkpoint inhibitors in older adults with advanced stage
                cancers: A meta-analysis. J Geriatr Oncol. 2019 May 22. Pii:
                S1879-4068(19)30089-X. doi:10.1016/j.jgo.2019.05.013. [Epub
                ahead of print].
              </p>
              <p>
                Kanesvaran R, Cordoba R, Maggiore R. Immunotherapy in Older
                Adults With Advanced Cancers: Implications for Clinical
                Decision-Making and Future Research. Am Soc Clin Oncol Educ
                Book. 2018;38:400-14.
              </p>
              <p>
                Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two
                geriatric screening tools in older patients with cancer. J Clin
                Oncol. 2014;32(1):19–26
              </p>
              <p>
                Kim JW, Lee YG, Hwang IG, et al. Predicting cumulative incidence
                of adverse events in older patients with cancer undergoing
                first-line palliative chemotherapy: Korean Cancer Study Group
                (KCSG) multicentre prospective study. Br J Cancer.
                2018;118:1169-75.
              </p>
              <p>
                Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann
                Intern Med. 1984;100:704-13.
              </p>
              <p>
                Lederman JHP, Gourley C, Friedlander M, et al. Olaparib
                maintenance therapy in platinum-sensitive relapsed ovarian
                cancer. N Engl J Med. 2012;366(15):1382-92.
              </p>
              <p>
                Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with
                mismatch-repair with mismatch-repair deficiency. N Engl J
                Med.2015;372:2509-20.
              </p>
              <p>
                Lichtman SM. Chemotherapy in the elderly. Semin Oncol.
                2004;31:160-74.
              </p>
              <p>
                Lichtman SM. Therapy inight: therapeutic challenges in the
                treatment of elderly patients. Nature Clinical Practice
                2006;3:86-93.
              </p>
              <p>
                Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of
                chemotherapy toxicity in older patients with cancer: the role of
                the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol.
                2015;6:272-9.
              </p>
              <p>
                McKenna RJ Sr Clinical aspects of cancer in the elderly.
                Treatment decisions, treatment choices, and follow-up. Cancer.
                1994;74(7 Suppl):2107-17.
              </p>
              <p>
                Muchnik E, Loh KP, Strawderman M, Magnuson A, et al. Immune
                checkpoint inhibitors in real-world treatment of older adults
                with non-small cell lung cancer. J Am Geriatr Soc.
                2019;67(5):905-12.
              </p>
              <p>
                Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and
                younger patients treated with adjuvant chemotherapy for
                node-positive breast cancer: the Cancer and Leukemia Group B
                Experience. J Clin Oncol. 2007;25:3699-704.
              </p>
              <p>
                Mohile SG, Hardt M, Tew W, et al. Toxicity of bevacizumab in
                combination with chemotherapy in older patients. Oncologist.
                2013;18:408-14.
              </p>
              <p>
                Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance
                therapy in platinum-sensitive, recurrent ovarian cancer. N Engl
                J Med. 2016;375(22):2154-64.
              </p>
              <p>
                Murry DJ, Riva L, Poplack DG, et al (1998) Impact of nutrition
                on pharmacokinetics of anti-neoplastic agents. Int J Cancer.
                1998; Suppl 11:48-51.
              </p>
              <p>
                Mohile SG, Dale W, Somerfield MR, et al. Practical assessment
                and management of vulnerabilities in older patients receiving
                chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin
                Oncol. 2018;36:2326-47.
              </p>
              <p>
                Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy
                of immune checkpoint inhibitors (ICIs) between younger and older
                patients: a systematic review and meta-analysis. Cancer Treat
                Rev. 2016;45:30-37.
              </p>
              <p>
                Ogino H, Hanibuchi M, Kakiuchi S, et al. Analysis of the
                prognostic factors of extensive disease small-cell lung cancer
                patients in Tokushima University Hospital. J Med Invest.
                2016;63(3–4):286-93.
              </p>
              <p>
                Paz-Ares L, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib
                in patients with EGFR mutation-positive advanced non-small-cell
                lung cancer: overall survival data form the pahse IIb LUX-Lung 7
                trial. Ann Oncol. 2017;28(2):270-7.
              </p>
              <p>
                Peters S, Camidge DR, Shaw AT, et al. Alectinib versus
                crizotinib in untreated ALK-positive non-small-cell lung cancer.
                N Engl J Med. 2017;377(9):829-38.
              </p>
              <p>
                Peeters M, Price TJ, Cervantes A, et al. Final results form a
                randomized phase 3 study of FOLFIRI +/- panitumumab for
                second-line treatment of metastatic colorectal cancer. Ann
                Oncol. 2014;25(1):107-16.
              </p>
              <p>
                Pietrantonio F, Cremolini C, Aprile G, et al. Single-agent
                panitumumab in frail elderly patients with advanced RAS and BRAF
                Wild-type colorectal cancer. challenging drug label to light up
                new hope. The Oncologist 2015;20:1261-65.
              </p>
              <p>
                Phister JE, Jue SG. Problems in the use of anticancer drugs in
                the elderly. Drugs. 1989;37:551-65.
              </p>
              <p>
                Poropatich K, Fontanarosa J, Samant S, et al. Cancer
                Immunotherapies: Are They as Effective in the Elderly. Drugs
                Aging. 2017;34:567-81.
              </p>
              <p>
                Pritchard KI, Burris HA, Ito Y, et al. Safety and efficacy of
                everolimus with exemestane vs. exemestane alone in elderly
                patients with HER2-negative, hormone receptor-positive breast
                cancer in BOLERO-2. Clin Breast Cancer. 2013;13(6):421-32.
              </p>
              <p>
                Raab GT, Lin A, Hillyer GC, et al. Use of bevacizumab for
                elderly patients with stage IV colon cancer: analysis of
                SEER-Medicare Data. Clin Colorectal Cancer. 2019; Jun 8. pii:
                S1533-0028(19)30157-4. doi: 10.1016/j.clcc.2019.05.008. [Epub
                ahead of print].
              </p>
              <p>
                Robert C, Schachter J, Long GV, et al; KEYNOTE-006
                investigators. Pembrolizumab versus ipilimumab in advanced
                melanoma. N Engl J Med.2015;372:2521-32.
              </p>
              <p>
                Robert C, Long GV, Brady B, et al. Nivolumab in previously
                untreated melanoma without BRAF mutation. N Engl J Med.
                2015;372:320-30.
              </p>
              <p>
                Repetto L. Greater risks of chemotherapy toxicity in elderly
                patients with cancer. J Support Oncol. 2003;1:18-24.
              </p>
              <p>
                Sastre J, Massuti B, Pulido G, et al. First-line single agent
                panitumumab in frail older patients with wild-type KRAS
                metastatic colorectal cancer and poor prognostic factors: a
                phase II study of the Spanish cooperative Group for the
                Treatment of digestive Tumors. Eur J Cancer 2015;51:1371-80.
              </p>
              <p>
                Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis
                of adjuvant chemotherapy for resected colon cancer in elderly
                patients. N Engl J Med. 2001;345(15):1091-97.
              </p>
              <p>
                Sager MA, Franke T, Inouye SK, et al. Functional outcomes of
                acute medical illness and hospitalization in older persons. Arch
                Intern Med. 1996;156:645-52.
              </p>
              <p>
                Sattar J, Kartolo A, Hopman WM, et al. The efficacy and toxicity
                of immune checkpoint inhibitors in a real-world older patient
                population. J Geriatr Oncol. 2019;10:411-14.
              </p>
              <p>
                Schrijvers D, Highley M, De Bruyn E, et al. Role of red blood
                cells in pharmacokinetics of chemotherapeutic agents. Anticancer
                Drugs. 1999;10:147-53.
              </p>
              <p>
                Shiroyama T, Nagatomo I, Koyama S, et al. Impact of sarcopenia
                in patients with advanced non-small cell lung cancer treated
                with PD-1 inhibitors: a preliminary retrospective study. Sci
                Rep. 2019;9:2447.
              </p>
              <p>
                Sud S, Lai P, Zhang T, et al. Chemotherapy in the oldest old:
                the feasibility of delivering cytotoxic therapy to patients 80
                years old and older. J Geriatr Oncol. 2015;6:395-400.
              </p>
              <p>
                Shahrokni A, Wu AJ, Carter J, et al. Long-term toxicity of
                cancer treatment in older patients. Clin Geriatr Med.
                2016;32:63-80.
              </p>
              <p>
                Singh H, Kim G, Maher VE, et al. FDA subset analysis of the
                safety of nivolumab in elderly patients with advanced cancer. J
                Clin Oncol. 2016;34 (suppl; abstr 10010).
              </p>
              <p>
                Spiegel DR, Schwartzberg L, Waterhouse D, et al. Is nivolumab
                safe and effective in elderly and PS2 patients with non-small
                cell lung cancer (NSCLC)?. Results of CheckMate 153. J. Thorac
                Oncol. 2017;12: A1287-S1288.
              </p>
              <p>
                Suzuki H, Hanai N, Nishikawa D, et al. The Charlson comorbidity
                index is a prognostic factor in sinonasal tract squamous cell
                carcinoma. Jpn J Clin Oncol. 2016;46(7):646-51.
              </p>
              <p>
                Tapia G, Townsend AR, Broadbridge VY, et al. Targeted therapies
                in elderly patients with metastatic colorectal cancer: a review
                of the evidence. Drugs Aging 2017;34:173-89.
              </p>
              <p>
                Terazawa T, Kato T, Goto M, et al. First-line single-agent
                panitumumab in frail elderly patients with wild-type RAS
                unresectable colorectal cancer: a phase II study protocol OGSG
                1602. BMC Cancer 2019;19:623.
              </p>
              <p>
                Tsuruo T, Naito M, Tomida A, et al. Molecular targeting therapy
                of cancer: drug resistance, apoptosis and survival signal.
                Cancer Sci. 2003;94:15-21.
              </p>
              <p>Thomas DR. Sarcopenia. Clin Geriatr Med. 2010;26:331-46.</p>
              <p>
                Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of
                aflibercept to fluorouracil, leucovorin, and irinotecan improves
                survival in a phase III randomized trial in patients with
                metastatic colorectal cancer previously treated with an
                oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-506.
              </p>
              <p>
                van Holstein Y, Kapiteijn E, Bastiaannet E, et al. Efficacy and
                adverse events of immunotherapy with checkpoint inhibitors in
                older patients with cancer. Drugs Aging.2019; Jul 18. doi:
                10.1007/s40266-019-00697-2. [Epub ahead of print].
              </p>
              <p>
                Wells JC, Tu D, SIu LL, et al. Outcomes of older patients (≥70
                years) treated with targeted therapy in metastatic
                chemorefractory colorectal cancer: Retrospective analysis of
                NCIC CTG CO.17 and CO.20. Clin Colorectal Cancer
                2018;18(1):e140-9.
              </p>
              <p>
                Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and
                trastuzumab with or without metronomic chemotherapy for older
                patients with HER-2 positive metastatic breast cancer (EORTC
                75111-10114): an open-label, randomised, phase 2 trial form the
                Elderly Task Force/Breast Cancer Group. Lancet Oncol.
                2018;19(3):323-36.
              </p>
              <p>
                Weiss SA, Han J, Darvishian F, et al. Impact of aging on host
                inmune response and survival inmelanoma: an analysis of 3
                patient cohorts. J Tranl Med. 2016;14:299.
              </p>
              <p>
                Zhang Q, Wang Z, Guo J, et al. Comparison of single-agent
                chemotherapy and targeted therapy to first-line treatment in
                patients aged 80 years and older with advanced non-small-cell
                lung cancer. Onco Targets Ther. 2015;8:893-98.
              </p>
              <p>
                Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule
                kinase inhibitors. Nat Rev Cancer. 2009;9:28-39.
              </p>
              <p>
                Zhao CJ, Li SL, Liu Q. Meta-analysis of molecular targeted
                agents in the treatment of elderly patients with metastatic
                colorectal cancer: Does the age matter?. J Cancer Res Ther.
                2018;14(8):79-84.
              </p>
            </div>
          </div>
        </div>

        <div class="ico-cabecera">
          <div class="ico-narrow-content">
            <div class="pager">
              <h3 class="text-center">
                <br />
              </h3>
            </div>
          </div>
        </div>
      </div>
    </div>

    <!-- jQuery -->
    <script src="js/jquery.min.js"></script>
    <!-- jQuery Easing -->
    <script src="js/jquery.easing.1.3.js"></script>
    <!-- Bootstrap -->
    <script src="js/bootstrap.min.js"></script>
    <!-- Carousel -->
    <script src="js/owl.carousel.min.js"></script>
    <!-- Stellar -->
    <script src="js/jquery.stellar.min.js"></script>
    <!-- Waypoints -->
    <script src="js/jquery.waypoints.min.js"></script>
    <!-- Counters -->
    <script src="js/jquery.countTo.js"></script>

    <!-- MAIN JS -->
    <script src="js/main.js"></script>
  </body>
</html>
